Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid  by Braud, Sandrine et al.
Activation of rabbit blood platelets by anandamide through its cleavage
into arachidonic acid
Sandrine Brauda, Cassian Bona, Lhousseine Touquib, Carine Mouniera;c;*
aUnite¤ des Venins, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
bUnite¤ de Pharmacologie Cellulaire/Unite¤ associe¤e INSERM U. 485, Institut Pasteur, Paris, France
cUniversite¤ de Cergy-Pontoise, De¤partement de Biologie, Cergy-Pontoise, France
Received 8 January 2000; received in revised form 2 March 2000
Edited by Pierre Jolles
Abstract Anandamide (ANA), a cannabinoid receptor ligand,
stimulated platelet aggregation at concentrations similar to those
of arachidonic acid (AA). The aggregating effect of ANA was
inhibited by aspirin but not by SR-141716, a cannabinoid
receptor antagonist. In addition, HU-210, a cannabinoid receptor
agonist, failed to induce platelet activation. Radiolabelling
experiments showed that exogenous ANA was cleaved by
platelets into AA through a phenylmethylsulfonyl fluoride
(PMSF)-sensitive pathway. In agreement, PMSF was shown to
abolish the aggregating effect of ANA. In conclusion, ANA is
able to induce platelet activation via its cleavage by a PMSF-
sensitive amidase activity, leading to the release of AA which in
turn activates platelets.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Anandamide (ANA), i.e. N-arachidonoyl-ethanolamine,
identi¢ed as a brain arachidonic acid (AA) derivative in var-
ious mammalian species, is a ligand for endogenous cannabi-
noid receptors [1^4]. Two major cannabinoid receptors have
been characterized: (i) the central cannabinoid receptor CB1
was ¢rst discovered in brain and more recently also found to
be present in testis and peripheral tissues [5^8] ; (ii) the ‘pe-
ripheral’ cannabinoid receptor CB2 is predominantly ex-
pressed in peripheral tissues, and particularly in cells of the
immune system [9,10]. When administered in vivo, ANA in-
duces antinociception, hypothermia, hypomotility and cata-
lepsy [11^14]. ANA may also be involved in pain initiation
[15] or sleep induction [16]. Recent studies have suggested that
ANA may be involved in immune [7,17,18], cardiovascular
[4,19] or reproductive functions [20,21]. However, the e¡ect
of ANA on isolated cells implicated in these processes is
poorly documented.
In brain, AA may be produced from ANA through the
action of a calcium-independent speci¢c amidase which be-
longs to the serine protease family, sensitive to phenylmethyl-
sulfonyl £uoride (PMSF) [22^25]. It has been reported that
ANA is stable in plasma, suggesting that the short half-life of
ANA after administration depends on its degradation by cells.
The presence of an amidase activity in cell types other than
neurons has been demonstrated for U937 cells [25] and leu-
kocytes [26]. However, whether this amidase is present in
blood platelets and mediates a possible e¡ect of ANA remains
to be investigated.
The proaggregant action of AA has been well established,
since its metabolism by cyclooxygenase and lipoxygenases
leads to the formation of various biologically active AA de-
rivatives such as thromboxane A2 (TxA2), and prostaglandins
(PG) G2, H2, and E2 [27^31]. Because ANA has an unmodi-
¢ed arachidonate backbone, it has been examined whether it
is a substrate for the enzymes that metabolize AA. It has been
shown in vitro that ANA is a substrate for porcine leukocyte
and human platelet puri¢ed 12-lipoxygenases, as well as for
rabbit reticulocyte and soybean 15 puri¢ed lipoxygenases [32].
Hampson et al. [33] have also demonstrated that brain cells
produce 12-hydroxyanandamide, an ANA-derived compound
resulting from the 12-lipoxygenase activity. Moreover, puri-
¢ed human cyclooxygenase 2 is able to transform ANA in
PGE2 ethanolamine [34].
It is of interest to examine the e¡ect of ANA on blood
platelets in order to determine if this compound may exert
some pharmacological actions on this cell type. Theoretically,
ANA might be able to induce platelet activation by three
di¡erent mechanisms: (i) after cleavage by cyclooxygenase
or lipoxygenase, (ii) after cleavage by an amidase leading to
the production of AA, and (iii) after direct binding to canna-
binoid-like receptors. Our study clearly shows that ANA in-
duced rabbit platelet activation that correlated with its cleav-
age into AA by a PMSF-sensitive amidase. We suggest that
ANA is a precursor of AA and derivatives, and thus may play
a role as a platelet aggregating agent.
2. Materials and methods
2.1. Materials
Thrombin was from Ho¡man-La Roche (Switzerland) and collagen
and platelet activating factor (PAF) were from Bachem (Switzerland).
Fibrinogen (grade L) was purchased from Kabi (Stockholm, Sweden)
and treated with diisopropyl £uorophosphate to inactivate pro-acti-
vating contaminants. Aspirin was from Sano¢-Synthelabo (France),
AA and ANA from Sigma Chemical Co. (St. Louis, MO, USA).
Compounds HU-210 and SQ-29548 were purchased from Tebu
(France). Compound SR-141716 was kindly provided by M. Mosse
from Sano¢-Synthelabo (France).
2.2. Preparation of washed rabbit platelets
Male rabbits (HY/CR strain from Charles River, Saint-Aubin-le's-
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Elbeuf, France) weighing 3^4 kg were bled from the central artery of
the ear on 5 mM EDTA. Platelets were washed as already reported
[35], and were resuspended at 4U108 cells/ml in Tyrode’s bu¡er (137
mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4,
1 mM MgCl2, 5.6 mM glucose, 0.25% gelatin, pH 7.4). When speci-
¢ed, platelets were incubated 15 min with 100 WM aspirin and then
washed.
2.3. Aggregation of washed platelets
Aggregation was monitored by light transmission in a PICA0
(Chrono-log corporation) as described [36]. Washed platelets were
incubated for 2 min with 2 mM CaCl2 plus 0.28 mg/ml ¢brinogen
(except when thrombin was used), then stimulated as detailed in the
legends of illustrations, and aggregation followed for 3 min. PAF and
collagen were used at concentrations of 40 nM and 10 Wg/ml, respec-
tively.
2.4. Labelling of platelets and measurements of AA release
As already described [35], aspirin-treated platelets were incubated
for 90 min at 37‡C with 0.2 WCi/ml of [3H]AA (from Amersham, Les
Ulis, France), then washed twice to remove the radioactivity that was
not incorporated. The labelled platelets were in Tyrode’s bu¡er (pH
7.4) and completed with 2 mM CaCl2 and 0.28 mg/ml ¢brinogen.
Aliquots (0.5 ml) of labelled platelets were incubated for 3 or 10 min
at 37‡C with 10 WM ANA in the absence or presence of 20 WM
PMSF, with 0.25 U/ml thrombin or with saline (control). The reac-
tions were stopped with 0.5 ml Tyrode’s solution (pH 7.4) containing
5 mM EDTA and 10 mg/ml bovine serum albumin pre-cooled at 4‡C.
Platelets were then removed by a 2 min centrifugation at 7800Ug, and
the radioactivity, in 100 Wl aliquots of the supernatant, was deter-
mined by liquid scintillation spectrophotometry.
2.5. Cleavage of exogenously added [3H]ANA into [3H]AA by blood
platelets
[3H]ANA ([arachidonyl 5,6,8,9,11,12,14,15-3H]ethanolamine from
NEN) at a speci¢c activity of 221 Ci/mmol was used as tracer. A
mixture of [3H]ANA:ANA (ratio 1:2000) was prepared at 1 mM
with a radioactivity of 0.1 mCi/ml. Then, 10 WM of [3H]ANA:ANA
(1:2000) was added to aspirin-pretreated platelets in the presence of
2 mM CaCl2 and ¢brinogen, with or without addition of PMSF. After
3 or 10 min, 200 Wl of the platelet suspension was collected. AA and
ANA were extracted twice by the method of Bligh and Dyer [37] and
the chloroform phases were pooled and applied to thin layer chroma-
tography plates (silica gel 60). The chromatography was performed
with hexane:ethyl acetate:H2O:acetic acid (50:100:100:20, v/v) in or-
der to separate ANA and AA adequately [22]. After detection by
iodine vapor, the spots corresponding to ANA and AA were scraped
o¡, and the radioactivity was determined by liquid scintillation spec-
trophotometry.
3. Results
3.1. Action of AA and ANA on platelet aggregation
As expected, AA induced platelet aggregation in a concen-
tration-dependent manner (Fig. 1) with an optimum at con-
centrations from 3 to 10 WM. At concentrations above 20 WM,
a progressive decrease in the aggregating activity of AA was
observed. Similar e¡ects were observed with ANA, the con-
centration^response curve of which was superimposed on that
of AA (Fig. 1). The loss of aggregating e¡ect at high concen-
trations of AA has been explained by the production of in-
hibitory prostaglandins such as PGE2 [27^31]. The fact that
this phenomenon was also observed with ANA suggests the
production of PGE2 from ANA occurred in blood platelets.
The presence of calcium is necessary for agonist-induced
platelet aggregation [27,28], since it allows the formation of
interplatelet bridges. The ¢brinogen also promotes the platelet
aggregation and is necessary in vivo and in vitro to observe a
proaggregant e¡ect by AA, collagen and PAF [27,28]. We
showed here that the aggregation of washed platelets by
ANA was dependent on the presence of calcium, since only
a shape change was observed in its absence (Fig. 2A). In the
absence of ¢brinogen, the aggregation was still observed but
to a lesser extent compared to that obtained in its presence
(data not shown).
Addition of AA to washed platelets, in the presence of
calcium and ¢brinogen, induced an immediate platelet aggre-
gation (Fig. 2B). In contrast, platelet aggregation induced by
an optimal concentration of ANA (10 WM) was initiated after
a lag time of 45^60 s (Fig. 2C). This delay might re£ect the
occurrence of an additional step necessary for ANA-induced
platelet activation.
We then examined whether this lag time was dependent on
the presence of calcium. Blood platelets incubated with ¢bri-
nogen in the absence of calcium received 10 WM of ANA, then
calcium was introduced at di¡erent time intervals. In the ab-
sence of calcium, only a shape change occurring after 45^60 s
was observed, as shown above. When calcium was introduced
2 and 4 min after the addition of ANA, the aggregation
started immediately (Fig. 2E,F). This result indicated that
the extracellular calcium was only required for the aggregating
e¡ect of ANA, but not for the step preceding this aggregation.
3.2. ANA-induced aggregation was abolished by aspirin and
PMSF pretreatment of blood platelets
Aspirin is known to inactivate cyclooxygenase irreversibly
in various cell types. This leads to the complete inhibition of
AA-induced platelet activation. Aspirin pretreatment of blood
platelets was performed in order to determine whether ANA-
induced aggregation was mediated by a similar pathway to
AA. Results in Table 1 show that ANA-induced shape change
and aggregation were completely blocked by aspirin. The ad-
dition of compound SQ-29548, a well-known TxA2 receptor
antagonist [38], completely abolished the aggregation induced
by ANA (53 þ 4% and 0% of light transmission in the absence
and in the presence of 1 WM SQ-29548, respectively, n = 3).
This suggests that ANA-induced platelet activation occurs
through a TxA2 receptor-dependent pathway, as described
for AA.
The amidase activity described in the brain to be involved
in the catabolism of ANA belongs to the PMSF-sensitive
serine protease family [22^25]. It was thus interesting to ex-
Fig. 1. Platelet aggregation induced by AA (R) and ANA (O).
Washed platelets were incubated for 2 min with 2 mM CaCl2 and
0.28 mg/ml ¢brinogen. AA and ANA were then added at the indi-
cated concentrations. Values are the means þ S.E.M. of three experi-
ments.
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amine the e¡ect of PMSF on platelet aggregation induced by
ANA. We observed that the addition of 20 WM PMSF com-
pletely abolished the aggregating e¡ect of ANA, as well as the
accompanying shape change. In contrast, PMSF was unable
to a¡ect the aggregation induced by thrombin and AA (Table
1), as well as collagen and PAF (data not shown). Since the
inhibitory e¡ect of PMSF was speci¢c for ANA-induced ag-
gregation, it is likely that PMSF interferes with an amidase
activity involved in the cleavage of ANA into AA.
3.3. [3H]ANA cleavage into [3H]AA correlated with platelet
activation induced by ANA
To further investigate whether platelets possess a PMSF-
sensitive amidase activity producing AA from exogenous
ANA, [3H]ANA (labelled on the AA moiety) was added to
platelets, and the appearance of [3H]AA was examined. Our
results showed that [3H]ANA was time-dependently converted
into a radioactive compound which comigrated with AA on
thin layer chromatography (Fig. 3A), and was concomitant
with a decrease in [3H]ANA content (data not shown). The
half-life of [3H]ANA in platelets was around 10 min in our
experimental conditions (Fig. 3A). The cleavage of ANA was
completely abolished when PMSF was added to platelets be-
fore the addition of [3H]ANA. Thus, we concluded that plate-
lets possess a speci¢c PMSF-sensitive amidase activity con-
verting ANA into AA, the latter being involved in platelet
activation.
Finally, a possible e¡ect of ANA via binding on a receptor
that might elicit liberation of endogenous AA, and conse-
quently platelet aggregation, was examined. We ¢rst investi-
gated whether the addition of ANA on [3H]AA-labelled plate-
lets, pretreated with aspirin, was able to release [3H]AA from
platelets. Aspirin was used in this experiment to block the
metabolism of [3H]AA and to avoid the production of AA
derivatives that could activate platelets and induce further AA
liberation. Our results showed that ANA failed to induce the
liberation of [3H]AA from platelets (Fig. 3B). Compound
HU-210, a CB1 and CB2 cannabinoid receptor agonist [39],
failed to induce platelet activation even at concentrations up
to 20 WM (Fig. 3C). Compound SR-141716, a CB1 receptor
antagonist [40], was unable to block the aggregating e¡ect
induced by ANA (Fig. 3C). These ¢ndings suggest that
ANA-induced aggregation does not occur via a cannabinoid
receptor-dependent pathway.
4. Discussion
In this study, we report that micromolar concentrations of
ANA stimulate platelets, leading to a shape change and ag-
gregation. We also show that AA and ANA concentration^
response curves are superimposed and that their activating
Fig. 2. Kinetic of ANA-induced platelet aggregation. Washed platelets were incubated for 2 min with 0.28 mg/ml ¢brinogen, and ANA was
added at the optimal concentration (10 WM). Then 2 mM CaCl2 was added at the indicated time. Representative recordings of platelet aggrega-
tion are shown.
Table 1
E¡ect of aspirin and PMSF on thrombin, ANA- and AA-induced
platelet aggregation
Thrombin
(0.25 U/ml)
ANA
(10 WM)
AA
(20 WM)
Control (saline) 46.6 þ 0.4 56.0 þ 2.1 40.0 þ 1.5
Aspirin (30 Wg/ml) 59.0 þ 3.8 0 þ 0 0 þ 0
PMSF (20 WM) 47.0 þ 0.8 0 þ 0 44.0 þ 5.1
Optimal concentrations of ANA and AA were used to determine
their e¡ect on platelet aggregation in the presence or absence of as-
pirin, and in the presence or absence of PMSF as compared to that
of thrombin. Values are the mean þ S.E.M. of three separate experi-
ments.
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e¡ects are abolished by pretreatment of platelets with aspirin.
This leads to the conclusion that cyclooxygenase is involved in
the action of ANA and it indicates that AA and ANA induce
platelet activation by similar mechanisms.
When added on blood platelets, AA immediately induces
platelet shape change and aggregation, while a lag time of
almost 1 min was observed with ANA (Fig. 2). This delay
may represent the time required for the cleavage of ANA
into AA. Indeed, a speci¢c amidase, sensitive to PMSF and
calcium-independent, has been described in brain able to
cleave ANA [22^25]. A low concentration of PMSF speci¢-
cally abolished the activating e¡ect of ANA on platelets. Fi-
nally, [3H]ANA was time-dependently converted into [3H]AA
through a process blocked by PMSF. Altogether, our obser-
vations support the hypothesis that ANA is cleaved by a
PMSF-sensitive amidase in platelets, and that this cleavage
correlates with the ANA-induced platelet activation. The ap-
pearance of AA will lead to the formation of AA derivatives,
such as TxA2 which is a potent platelet activator through
binding to a speci¢c receptor. In agreement, compound SQ-
29548, a well-known TxA2 receptor antagonist, completely
abolished the activating e¡ect of ANA, further supporting
the conclusion that ANA-induced platelet activation occurs
via an AA-dependent pathway.
It has been shown that ANA exerts various peripheral ef-
fects through binding to either CB1 or CB2 receptors [9,10].
Binding of ANA or cannabinoids on a receptor expressed in
¢broblasts increased AA release via the stimulation of the
mitogen-activated protein kinase signalling pathway [41]. In
order to examine whether ANA induces AA release via a
receptor-dependent mechanism, platelets were pretreated
with aspirin and labelled with [3H]AA, and then stimulated
with ANA. We did not observe any [3H]AA liberation indi-
cating that the activating e¡ect of ANA is not due to the
release of endogenous AA from the platelet membrane via
ANA binding to a receptor. In agreement, a highly potent
cannabinoid receptor agonist (compound HU-210) failed to
activate blood platelets and a cannabinoid receptor antagonist
(compound SR-141716) was unable to block ANA-induced
platelet aggregation. These results provide further reasons to
discard the hypothesis that the amidase activity might be ac-
tivated after ANA binding on a receptor.
It is obvious from our study that the platelet activating
e¡ect of ANA is based on its cleavage into AA. However,
we cannot exclude that a part of exogenous ANA might be
directly metabolized by either cyclooxygenase or 12-lipoxy-
genase in platelets as reported [32^34], especially because we
did not observe a total cleavage of ANA. Recently, ANA has
been shown to be metabolized to a limited extent by pre-
activated human platelets into 12(S)-HAEA [42], but no
data are available on ANA metabolization in resting platelets.
However, since the activating e¡ect of ANA is completely
abolished by PMSF at a concentration which does not inter-
fere with the e¡ect of AA, it is likely that the main action of
PMSF is to inhibit the amidase activity that catalyzes the
cleavage of ANA into AA.
In conclusion, ANA is a potent aggregating agent in rabbit
platelets via its cleavage into AA. However, the physiological
and/or pathophysiological signi¢cance of platelet activation
by ANA has still to be examined. Together with recent studies
showing the involvement of ANA in in£ammatory, immune
or cardiovascular systems, our results support the hypothesis
Fig. 3. E¡ect of ANA on [3H]AA release and e¡ect of compounds
HU-210 and SR-141716 on ANA-induced platelet aggregation.
A: The appearance of [3H]AA was measured after addition of
10 WM [3H]ANA on aspirin-treated platelets in the presence or ab-
sence of 20 WM PMSF. B: The liberation of [3H]AA from platelet
membrane was measured after addition of 10 WM ANA on aspirin-
treated platelets labelled with [3H]AA in the absence or presence of
20 WM PMSF. C: The e¡ect on blood platelets of 4 WM ANA,
20 WM HU-210, and 4 WM ANA in the presence of 4 WM SR-
141716 was measured in the absence of aspirin. Values are the
means þ S.E.M. of three experiments.
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that ANA may play important roles in functions other than
those described in the nervous system.
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